|
Sep 26, 2022
|
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
|
|
|
Sep 01, 2022
|
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
|
|
|
Aug 24, 2022
|
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
|
|
|
Aug 11, 2022
|
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases
|
|
|
Aug 02, 2022
|
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
|
|
|
Jul 28, 2022
|
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
|
|
|
Jul 22, 2022
|
AC Immune Announces Upcoming Presentations at the Alzheimer’s Association International Conference
|
|
|
Jun 24, 2022
|
AC Immune Holds Annual General Meeting of Shareholders
|
|
|
Jun 16, 2022
|
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
|
|
|
May 31, 2022
|
AC Immune to Present at the 2022 Jefferies Healthcare Conference
|
|